Congratulations to the team!
Fantastic success on the way to bring the new therapy from the lab to the market.
“Super macrophages” against cancer 🧬
Prof. Michael Sieweke, Dr. Anke Fuchs, and Dr. Angela Jacobi are developing a new immune cell therapy targeting solid tumors. Backed by €2.5M from the EIC, StemPhage aims to bring this approach closer to clinical use 🔬
Read more ➡️ tud.link/vwwmxg
#CMCBnews
TUD | Center for Molecular and Cellular Bioengineering (CMCB)
TUD | Center for Regenerative Therapies Dresden (CRTD)
